NASDAQ:PRLD

Prelude Therapeutics Q2 2025 Earnings Results & Report

Prelude Therapeutics logo
$3.32 -0.09 (-2.64%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.32 0.00 (-0.15%)
As of 11/17/2026 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.41 versus the -$0.45 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Prelude Therapeutics EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Prelude Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prelude Therapeutics Q2 2025 Earnings FAQ

Prelude Therapeutics (NASDAQ:PRLD) reported earnings of -$0.41 per share for Q2 2025, beating the consensus estimate of -$0.45. The report was announced on Thursday, August 14, 2025.

Prelude Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Prelude Therapeutics (PRLD) Expected to Release Earnings on Wednesday
See More Prelude Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email.

About Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival.

Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Founded in 2016 and based in Wilmington, Delaware, Prelude conducts its drug discovery and development work in the United States. Its programs are intended to address unmet needs in oncology through targeted approaches.

View Prelude Therapeutics Profile